A 14 Week Randomized Parallel Group Placebo-Controlled Double-Blind Multicentre Study Of Fesoterodine 8 Mg In Overactive Bladder Patients With Sub-Optimal Response To Tolterodine 4 Mg Extended Release (ER).

Trial Profile

A 14 Week Randomized Parallel Group Placebo-Controlled Double-Blind Multicentre Study Of Fesoterodine 8 Mg In Overactive Bladder Patients With Sub-Optimal Response To Tolterodine 4 Mg Extended Release (ER).

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2014

At a glance

  • Drugs Fesoterodine (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms AFTER
  • Sponsors Pfizer
  • Most Recent Events

    • 30 Aug 2013 Results presented at the 43rd Annual Meeting of the International Continence Society.
    • 19 Mar 2013 Results presented at the 28th Congress of the European Association of Urology.
    • 03 Aug 2012 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top